spacer
home > > autumn 2008 > home work
PUBLICATIONS


Home Work

In recent decades the types of therapy in research and the marketplace have undergone some radical transformations. Where most therapies were once squarely aimed at endemic diseases of the West, the recent biotechnology revolution has hugely increased the number of therapeutic targets, with more complex medicines – often parenteral – aimed at less common illnesses or at more specific sub groups of patients with more common conditions. For example, we are seeing oncology therapies targeting smaller sub groups of patients, the rise of therapies for orphan indications, the targeting of antibodies and proteins for specific complications of illness such as preventing SLE crisis and so on. The drive towards community medicine means an infrastructure has grown up to administer these medicines in the home and to run clinical trials in the same way.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Graham Wylie is CEO of the Medical Research Network Ltd, an affiliate company of Healthcare at Home. Graham, who trained as a physician, has 18 years of experience in clinical trials, starting with 10 years at Pfizer in clinical development and corporate HQ, with roles ranging from project management of trials to global implementation of standard trial processes and IT tools. He then joined Parexel International in 1999 as Medical Director for Northern Europe, progressing to Vice President of Account Management for Europe by 2003. In 2005 he joined Healthcare at Home to develop their clinical trials activities into a full business unit, known as ‘The Medical Research Network’, spinning the division off as a separate company in 2006.
spacer
Dr Graham Wylie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

Keele, UK and Matfors, Sweden, 30 March 2020: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic. Partners in the consortium also include Karolinska University Hospital, Public Health Authority (FoHM), IGEA, Adlego AB and Giessen University.
More info >>

White Papers

Systems Engineering for Complex Portable Medical Device Development

Phillips-Medisize

As the demand for complex, portable medical devices continues to grow, reducing risk and increasing efficiency during the development of these products should be paramount. Taking a systems-engineering (SE) approach to development provides a holistic, organized, and deliberate method for identifying as well as reducing both patient and business risks early in the process. Furthermore, it facilitates efficient progression throughout the entire product development life cycle.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement